Dr Benjamin Mullish
Consultant in Hepatology and Gastroenterology
Digestive Health
Sub-specialties: Hepatology, Gastroenterology.
02036532009
Overview
Dr Benjamin Mullish is a Consultant in Hepatology and Gastroenterology at Welbeck Digestive Health, and has specialist clinical expertise in fatty liver disease, chronic liver disease/ cirrhosis, and general hepatology. He also has a particular clinical and research interest in the contribution of the gut microbiome to improve health (including via faecal microbiota transplant (FMT)).
About Dr Benjamin Mullish
Benjamin is a Consultant Hepatologist at St Mary’s Hospital, London (part of Imperial College Healthcare NHS Trust), where he contributes to the specialist regional clinic for metabolic dysfunction-related steatotic liver disease (MASLD). He also undertakes ward and clinic work across all aspects of hepatology and performs endoscopy. In addition, he is a Research Fellow in the Division of Digestive Diseases at Imperial College London, where he plays an integral role in an active research group investigating the gut microbiome, carrying out both laboratory work and clinical trials across a variety of medical conditions. He is Co-Director of the Imperial FMT service and has contributed to a range of consensus documents and guidelines related to microbiome diagnostics and therapeutics.
Benjamin graduated in Medicine from the University of Cambridge with Double First Class Honours and a Foundation Scholarship, before undertaking combined clinical and academic training in gastroenterology, hepatology, and general internal medicine in London. During his training, he obtained a PhD from Imperial College London for research into the mechanisms by which FMT (and other microbiome-related therapies) exert their therapeutic effects. He has secured competitive research fellowships and grants from the Medical Research Council.
Benjamin has received a number of national and international awards, including the British Society of Gastroenterology Young Gastroenterologist of the Year Award and the United European Gastroenterology Rising Star Award. He has co-authored more than 150 peer-reviewed publications and regularly presents his research at leading medical conferences. He also contributes to both undergraduate and postgraduate teaching programmes at Imperial College London.
Areas of Expertise
Dr Benjamin Mullish treats the following conditions:
- General hepatology
- Liver diseases
- Metabolic dysfunction-associated steatotic liver disease
- Alcohol-associated liver disease
- Cirrhosis
- C. difficile infection
He offers the following tests and treatments:
Additional Information
Dr Benjamin Mullish holds the following qualifications: MB BChir MA PhD MRCP AFHEA
He is an active member of:
- Member of the Royal College of Physicians
- Member of the British Society of Gastroenterology
- Member of the British Association for Study of the Liver
- Member of the European Association for the Study of the Liver
- Steering Group, European FMT Network
Dr Mullish currently holds clinical posts at:
- Consultant in Hepatology and Gastroenterology, Welbeck London
- Honorary Consultant in Hepatology and Gastroenterology at St Mary's Hospital London, Imperial College Healthcare
He is the recipient of the following professional awards:
- Young Gastroenterologist of the Year, Clinical and Translational Science - British Society of Gastroenterology, 2019.
- Winner, Young Investigators Award for Microbiome Researchers - Pharmabiotic Research Institute (PRI)-Institut Mérieux, 2020.
- Rising Star Award - United European Gastroenterology (UEG), 2022
Research Highlights
Dr Mullish's notable publications can be found below:
- Porcari S., Mullish B.H., Asnicar F., et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology and Hepatology (2025);10(2):154-167, doi: https://doi.org/10.1016/S2468-1253(24)00311-X
- Mullish B.H., Thursz M.R. Alcohol-associated liver disease: emerging therapeutic strategies. Hepatology (2024);80(6):1372-1389, doi: 10.1097/HEP.0000000000000986.
- Mullish B.H., Merrick B., Quraishi M.N., et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut (2024);73(7):1052-1075, doi: 10.1136/gutjnl-2023-331550.
- Forlano R., Martinez-Gili L., Takis P..., Mullish B.H., Manousou P. Disruption of gut barrier integrity and host-microbiome interactions underlying MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes (2024);16(1):2304157, doi: 10.1080/19490976.2024.2304157.
- Routy B., Lenehan J.G., Miller J W.H..., Mullish B.H., Silverman M.S., Burton J.P., Maleki Vareki S. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine (2023);29(8):2121-2132, doi: 10.1038/s41591-023-02453-x
Reviews
Major insurers served
If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.
